7 results
Forecasting Weed Distributions using Climate Data: A GIS Early Warning Tool
- Catherine S. Jarnevich, Tracy R. Holcombe, David T. Barnett, Thomas J. Stohlgren, John T. Kartesz
-
- Journal:
- Invasive Plant Science and Management / Volume 3 / Issue 4 / December 2010
- Published online by Cambridge University Press:
- 20 January 2017, pp. 365-375
-
- Article
- Export citation
-
The number of invasive exotic plant species establishing in the United States is continuing to rise. When prevention of exotic species from entering into a country fails at the national level and the species establishes, reproduces, spreads, and becomes invasive, the most successful action at a local level is early detection followed by eradication. We have developed a simple geographic information system (GIS) analysis for developing watch lists for early detection of invasive exotic plants that relies upon currently available species distribution data coupled with environmental data to aid in describing coarse-scale potential distributions. This GIS analysis tool develops environmental envelopes for species based upon the known distribution of a species thought to be invasive and represents the first approximation of its potential habitat while the necessary data are collected to perform more in-depth analyses. To validate this method we looked at a time series of species distributions for 66 species in Pacific Northwest and northern Rocky Mountain counties. The time series analysis presented here did select counties that the invasive exotic weeds invaded in subsequent years, showing that this technique could be useful in developing watch lists for the spread of particular exotic species. We applied this same habitat-matching model based upon bioclimatic envelopes to 100 invasive exotics with various levels of known distributions within continental U.S. counties. For species with climatically limited distributions, county watch lists describe county-specific vulnerability to invasion. Species with matching habitats in a county would be added to that county's list. These watch lists can influence management decisions for early warning, control prioritization, and targeted research to determine specific locations within vulnerable counties. This tool provides useful information for rapid assessment of the potential distribution based upon climate envelopes of current distributions for new invasive exotic species.
An evidence-based algorithm for the utility of FDG-PET for diagnosing Alzheimer's disease according to presence of medial temporal lobe atrophy
- Michael J. Firbank, Jim Lloyd, David Williams, Robert Barber, Sean J. Colloby, Nicky Barnett, Kirsty Olsen, Christopher Davison, Cam Donaldson, Karl Herholz, John T. O'Brien
-
- Journal:
- The British Journal of Psychiatry / Volume 208 / Issue 5 / May 2016
- Published online by Cambridge University Press:
- 02 January 2018, pp. 491-496
- Print publication:
- May 2016
-
- Article
-
- You have access Access
- HTML
- Export citation
-
Background
Imaging biomarkers for Alzheimer's disease include medial temporal lobe atrophy (MTLA) depicted on computed tomography (CT) or magnetic resonance imaging (MRI) and patterns of reduced metabolism on fluorodeoxyglucose positron emission tomography (FDG-PET).
AimsTo investigate whether MTLA on head CT predicts the diagnostic usefulness of an additional FDG-PET scan.
MethodParticipants had a clinical diagnosis of Alzheimer's disease (n = 37) or dementia with Lewy bodies (DLB; n = 30) or were similarly aged controls (n = 30). We visually rated MTLA on coronally reconstructed CT scans and, separately and blind to CT ratings, abnormal appearances on FDG-PET scans.
ResultsUsing a pre-defined cut-off of MTLA ⩾5 on the Scheltens (0–8) scale, 0/30 controls, 6/30 DLB and 23/30 Alzheimer's disease had marked MTLA. FDG-PET performed well for diagnosing Alzheimer's disease v. DLB in the low-MTLA group (sensitivity/specificity of 71%/79%), but in the high-MTLA group diagnostic performance of FDG-PET was not better than chance.
ConclusionsIn the presence of a high degree of MTLA, the most likely diagnosis is Alzheimer's disease, and an FDG-PET scan will probably not provide significant diagnostic information. However, in cases without MTLA, if the diagnosis is unclear, an FDG-PET scan may provide additional clinically useful diagnostic information.
Contributors
- Edited by Georg Gasser, Matthias Stefan
-
- Book:
- Personal Identity
- Published online:
- 05 December 2012
- Print publication:
- 15 November 2012, pp x-x
-
- Chapter
- Export citation
Contributors
-
- By Aakash Agarwala, Linda S. Aglio, Rae M. Allain, Paul D. Allen, Houman Amirfarzan, Yasodananda Kumar Areti, Amit Asopa, Edwin G. Avery, Patricia R. Bachiller, Angela M. Bader, Rana Badr, Sibinka Bajic, David J. Baker, Sheila R. Barnett, Rena Beckerly, Lorenzo Berra, Walter Bethune, Sascha S. Beutler, Tarun Bhalla, Edward A. Bittner, Jonathan D. Bloom, Alina V. Bodas, Lina M. Bolanos-Diaz, Ruma R. Bose, Jan Boublik, John P. Broadnax, Jason C. Brookman, Meredith R. Brooks, Roland Brusseau, Ethan O. Bryson, Linda A. Bulich, Kenji Butterfield, William R. Camann, Denise M. Chan, Theresa S. Chang, Jonathan E. Charnin, Mark Chrostowski, Fred Cobey, Adam B. Collins, Mercedes A. Concepcion, Christopher W. Connor, Bronwyn Cooper, Jeffrey B. Cooper, Martha Cordoba-Amorocho, Stephen B. Corn, Darin J. Correll, Gregory J. Crosby, Lisa J. Crossley, Deborah J. Culley, Tomas Cvrk, Michael N. D'Ambra, Michael Decker, Daniel F. Dedrick, Mark Dershwitz, Francis X. Dillon, Pradeep Dinakar, Alimorad G. Djalali, D. John Doyle, Lambertus Drop, Ian F. Dunn, Theodore E. Dushane, Sunil Eappen, Thomas Edrich, Jesse M. Ehrenfeld, Jason M. Erlich, Lucinda L. Everett, Elliott S. Farber, Khaldoun Faris, Eddy M. Feliz, Massimo Ferrigno, Richard S. Field, Michael G. Fitzsimons, Hugh L. Flanagan Jr., Vladimir Formanek, Amanda A. Fox, John A. Fox, Gyorgy Frendl, Tanja S. Frey, Samuel M. Galvagno Jr., Edward R. Garcia, Jonathan D. Gates, Cosmin Gauran, Brian J. Gelfand, Simon Gelman, Alexander C. Gerhart, Peter Gerner, Omid Ghalambor, Christopher J. Gilligan, Christian D. Gonzalez, Noah E. Gordon, William B. Gormley, Thomas J. Graetz, Wendy L. Gross, Amit Gupta, James P. Hardy, Seetharaman Hariharan, Miriam Harnett, Philip M. Hartigan, Joaquim M. Havens, Bishr Haydar, Stephen O. Heard, James L. Helstrom, David L. Hepner, McCallum R. Hoyt, Robert N. Jamison, Karinne Jervis, Stephanie B. Jones, Swaminathan Karthik, Richard M. Kaufman, Shubjeet Kaur, Lee A. Kearse Jr., John C. Keel, Scott D. Kelley, Albert H. Kim, Amy L. Kim, Grace Y. Kim, Robert J. Klickovich, Robert M. Knapp, Bhavani S. Kodali, Rahul Koka, Alina Lazar, Laura H. Leduc, Stanley Leeson, Lisa R. Leffert, Scott A. LeGrand, Patricio Leyton, J. Lance Lichtor, John Lin, Alvaro A. Macias, Karan Madan, Sohail K. Mahboobi, Devi Mahendran, Christine Mai, Sayeed Malek, S. Rao Mallampati, Thomas J. Mancuso, Ramon Martin, Matthew C. Martinez, J. A. Jeevendra Martyn, Kai Matthes, Tommaso Mauri, Mary Ellen McCann, Shannon S. McKenna, Dennis J. McNicholl, Abdel-Kader Mehio, Thor C. Milland, Tonya L. K. Miller, John D. Mitchell, K. Annette Mizuguchi, Naila Moghul, David R. Moss, Ross J. Musumeci, Naveen Nathan, Ju-Mei Ng, Liem C. Nguyen, Ervant Nishanian, Martina Nowak, Ala Nozari, Michael Nurok, Arti Ori, Rafael A. Ortega, Amy J. Ortman, David Oxman, Arvind Palanisamy, Carlo Pancaro, Lisbeth Lopez Pappas, Benjamin Parish, Samuel Park, Deborah S. Pederson, Beverly K. Philip, James H. Philip, Silvia Pivi, Stephen D. Pratt, Douglas E. Raines, Stephen L. Ratcliff, James P. Rathmell, J. Taylor Reed, Elizabeth M. Rickerson, Selwyn O. Rogers Jr., Thomas M. Romanelli, William H. Rosenblatt, Carl E. Rosow, Edgar L. Ross, J. Victor Ryckman, Mônica M. Sá Rêgo, Nicholas Sadovnikoff, Warren S. Sandberg, Annette Y. Schure, B. Scott Segal, Navil F. Sethna, Swapneel K. Shah, Shaheen F. Shaikh, Fred E. Shapiro, Torin D. Shear, Prem S. Shekar, Stanton K. Shernan, Naomi Shimizu, Douglas C. Shook, Kamal K. Sikka, Pankaj K. Sikka, David A. Silver, Jeffrey H. Silverstein, Emily A. Singer, Ken Solt, Spiro G. Spanakis, Wolfgang Steudel, Matthias Stopfkuchen-Evans, Michael P. Storey, Gary R. Strichartz, Balachundhar Subramaniam, Wariya Sukhupragarn, John Summers, Shine Sun, Eswar Sundar, Sugantha Sundar, Neelakantan Sunder, Faraz Syed, Usha B. Tedrow, Nelson L. Thaemert, George P. Topulos, Lawrence C. Tsen, Richard D. Urman, Charles A. Vacanti, Francis X. Vacanti, Joshua C. Vacanti, Assia Valovska, Ivan T. Valovski, Mary Ann Vann, Susan Vassallo, Anasuya Vasudevan, Kamen V. Vlassakov, Gian Paolo Volpato, Essi M. Vulli, J. Matthias Walz, Jingping Wang, James F. Watkins, Maxwell Weinmann, Sharon L. Wetherall, Mallory Williams, Sarah H. Wiser, Zhiling Xiong, Warren M. Zapol, Jie Zhou
- Edited by Charles Vacanti, Scott Segal, Pankaj Sikka, Richard Urman
-
- Book:
- Essential Clinical Anesthesia
- Published online:
- 05 January 2012
- Print publication:
- 11 July 2011, pp xv-xxviii
-
- Chapter
- Export citation
Contributors
-
- By Basem Abdelmalak, Joseph Abdelmalak, Alaa A. Abd-Elsayed, David L. Adams, Eric E. Adelman, Maged Argalious, Endrit Bala, Gene H. Barnett, Sheron Beltran, Andrew Bielaczyc, William Bingaman, James M. Blum, Alina Bodas, Vera Borzova, Richard Bowers, Adam Brown, Chad M. Brummett, Alexandra S. Bullough, James F. Burke, Juan P. Cata, Neeraj Chaudhary, Michael J. Claybon, Miguel Cruz, Milind Deogaonkar, Vikram Dhawan, Thomas Didier, D. John Doyle, Zeyd Ebrahim, Hesham Elsharkawy, Wael Ali Sakr Esa, Ehab Farag, Ryen D. Fons, Joseph J. Gemmete, Matt Giles, Phil Gillen, Goodarz Golmirzaie, Marcos Gomes, Lisa Grilly, Maged Guirguis, David W. Healy, Heather Hervey-Jumper, Shawn L. Hervey-Jumper, Paul E. Hilliard, Samuel A. Irefin, George K. Istaphanous, Teresa L. Jacobs, Ellen Janke, Greta Jo, James W. Jones, Rami Karroum, Allen Keebler, Stephen J. Kimatian, Colleen G. Koch, Robert Scott Kriss, Andrea Kurz, Jia Lin, Michael D. Maile, Negmeldeen F. Mamoun, Mariel Manlapaz, Edward Manno, Donn Marciniak, Piyush Mathur, Nicholas F. Marko, Matthew Martin, George A. Mashour, Marco Maurtua, Scott T. McCardle, Julie McClelland, Uma Menon, Paul S. Moor, Laurel E. Moore, Ruairi Moulding, Dileep R. Nair, Todd Nelson, Julie Niezgoda, Edward Noguera, Jerome O’Hara, Aditya S. Pandey, Mauricio Perilla, Paul Picton, Marc J. Popovich, J. Javier Provencio, Venkatakrishna Rajajee, Mohit Rastogi, Stacy Ritzman, Lauryn R. Rochlen, Leif Saager, Vivek Sabharwal, Oren Sagher, Kenneth Saliba, Milad Sharifpour, Lesli E. Skolarus, Paul Smythe, Wolf H. Stapelfeldt, William R. Stetler, Peter Stiles, Vijay Tarnal, Khoi D. Than, B. Gregory Thompson, Alparslan Turan, Christopher R. Turner, Justin Upp, Sumeet Vadera, Jennifer Vance, Anthony C. Wang, Robert J. Weil, Marnie B. Welch, Karen K. Wilkins, Erin S. Williams, George N. Youssef, Asma Zakaria, Sherif S. Zaky, Andrew Zura
- Edited by George A. Mashour, Ehab Farag
-
- Book:
- Case Studies in Neuroanesthesia and Neurocritical Care
- Published online:
- 03 May 2011
- Print publication:
- 03 February 2011, pp x-xvi
-
- Chapter
- Export citation
Substance use in a population-based clinic sample of people with first-episode psychosis
- Jennifer H. Barnett, Ursula Werners, Sandra M. Secher, Katherine E. Hill, Rossa Brazil, Kim Masson, David E. Pernet, James B. Kirkbride, Graham K. Murray, Ed. T. Bullmore, Peter B. Jones
-
- Journal:
- The British Journal of Psychiatry / Volume 190 / Issue 6 / June 2007
- Published online by Cambridge University Press:
- 02 January 2018, pp. 515-520
- Print publication:
- June 2007
-
- Article
-
- You have access Access
- HTML
- Export citation
-
Background
Substance use is implicated in the cause and course of psychosis.
AimsTo characterise substance and alcohol use in an epidemiologically representative treatment sample of people experiencing a first psychotic episode in south Cambridgeshire.
MethodCurrent and lifetime substance use was recorded for 123 consecutive referrals to a specialist early intervention service. Substance use was compared with general population prevalence estimates from the British Crime Survey.
ResultsSubstance use among people with first-episode psychosis was twice that of the general population and was more common in men than women. Cannabis abuse was reported in 51% of patients (n=62) and alcohol abuse in 43% (n=53). More than half (n=68, 55%) had used Class A drugs, and 38% (n=43) reported polysubstance abuse. Age at first use of cannabis, cocaine, ecstasy and amphetamine was significantly associated with age at first psychotic symptom.
ConclusionsSubstance misuse is present in the majority of people with first-episode psychosis and has major implications for management. The association between age at first substance use and first psychotic symptoms has public health implications.
4 - Quality control in flow cytometry
-
- By David Barnett, Royal Hallamshire Hospital, Sheffield, John T. Reilly, Royal Hallamshire Hospital, Sheffield
- Edited by Desmond A. McCarthy, Queen Mary University of London, Marion G. Macey
-
- Book:
- Cytometric Analysis of Cell Phenotype and Function
- Published online:
- 06 January 2010
- Print publication:
- 01 November 2001, pp 74-88
-
- Chapter
- Export citation
-
Summary
Introduction
Flow cytometry, during the 1990s has become an integral part of diagnostic pathology. Indeed, many pathology laboratories currently use flow cytometry routinely to provide diagnostic and therapeutic support for clinicians treating a wide variety of malignant and nonmalignant disorders. Leukaemia immunophenotyping and the monitoring of lymphocyte subset counts are two of the most common uses, while flow cytometry is being increasingly used to determine the optimum time for peripheral blood stem cell (PBSC) harvesting, as well as for leukocyte and reticulocyte counting, platelet analysis (e.g. Bernard–Soulier and Glanzmann's syndrome) and red cell analysis (e.g. paroxysmal nocturnal hemoglobinuria and feto–maternal hemorrhage). In the twenty-first century, the flow cytometer is poised to revolutionise DNA and RNA molecular analysis through technologies such as multiplexing. The need to have instrument and methodological quality control procedures in place has become paramount as the use of the flow cytometer increases in the clinical setting. These proceduresmust be used in such a manner that they underpin the quality of results generated and should be performed frequently enough to identify problem areas. Consequently, it is essential to have both internal quality control (IQC) and external quality assessment (EQA) procedures in place. This chapter will focus on the current issues of IQC and EQA and highlight problems that may manifest during flow cytometric procedures.
Internal quality control
IQC can be defined as a set of procedures that monitor the instrument, analytical method and operator performance, as well as validating the reports generated. Such procedures are generally performed on a frequent enough basis to ensure that drift, or bias, can be detected and they should be supported by fully documented standard operating procedures.